Abstract 3005
Background
In PREVAIL, pts with progressive mCRPC following ADT had significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) on ENZ vs PL (Beer TM et al, N Engl J MED, 2014). In the current study, the efficacy and safety of ENZ vs PL were evaluated in a similar patient population in China, Taiwan, Hong Kong and South Korea.
Methods
Pts with asymptomatic/mildly symptomatic progressive mCRPC following ADT were randomised 1:1 to ENZ (160 mg/day) or PL. The primary endpoint was time to prostate-specific antigen (PSA) progression (time from randomisation to PSA progression or death). The secondary endpoints were OS (time from randomisation to death) and rPFS (time from randomisation to radiographic progression). An interim analysis was planned following 169 PSA progression events. The unstratified Cox proportional hazards model (covariate = treatment group) and log-rank test (2-sided significance level = 0.011, primary; 0.05, secondary) were used. Safety was assessed by recording adverse events (AE).
Results
409 pts from 49 centres were randomised (209 ENZ, 200 PL). Baseline characteristics were balanced between treatment groups. 169 PSA progression events occurred. Median time to PSA progression was 7.5 months in the ENZ arm vs 2.9 for PL (HR 0.36; 95% CI 0.27, 0.50; p
Conclusions
ENZ showed significantly improved time to PSA progression over PL and was generally well tolerated. The trial was stopped as it had reached its primary objective.
Clinical trial identification
ClinicalTrials.gov NCT02294461; First received: November 13, 2014; Last updated: November 25, 2015
Legal entity responsible for the study
Astellas Pharma, Inc.
Funding
Astellas Pharma, Inc. and Medivation, Inc.
Disclosure
Y-S. Pu: The author discloses that they received funding from Astellas Pharma Inc. for clinical studies.
S. Yamada, S. Noda: The author declares that they own stocks in, and are an employee of, Astellas Pharma Inc.
All other authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract